

**Community Advisory Board Meeting**  
**September 29, 2020**  
**9:00am - 11:00am**  
**Zoom Conference Call**

**Participants**

Name	Affiliation	CAB Role	Email Address
James Jackson	Western & Southern Life	CAB Chair	<a href="mailto:jjackson2@hotmail.com">jjackson2@hotmail.com</a>
Judi Patterson	Case Manager, Mental Health America	CAB Co-Chair	<a href="mailto:jpatterson@mhasd.org">jpatterson@mhasd.org</a>
Jamila K. Stockman	Associate Professor and Vice Chief, UC San Diego, Division of Infectious Diseases & Global Public Health	Director, Disparities Core and CAB	<a href="mailto:jstockman@health.ucsd.edu">jstockman@health.ucsd.edu</a>
Susan Little	Professor, UC San Diego, Division of Infectious Diseases & Global Public Health	Director of the CFAR Ending the HIV Epidemic Scientific Working Group	<a href="mailto:slittle@health.ucsd.edu">slittle@health.ucsd.edu</a>
Elizabeth Johnson	Administrative Director, Center for AIDS Research	CAB Member	<a href="mailto:liz@health.ucsd.edu">liz@health.ucsd.edu</a>
Laramie Smith	Assistant Professor, UC San Diego, Division of Infectious Diseases & Global Public Health	Guest	<a href="mailto:lrs003@health.ucsd.edu">lrs003@health.ucsd.edu</a>
Kiyomi Tsuyuki	Assistant Professor, UC San Diego, Division of Infectious Disease & Global Public Health, UC San Diego	CAB Member	<a href="mailto:ketsuyuki@health.ucsd.edu">ketsuyuki@health.ucsd.edu</a>
Janine V. Lopez	UC San Diego, Division of Infectious Diseases & Global Public Health	Research Associate, Disparities Core	<a href="mailto:jvlopez@health.ucsd.edu">jvlopez@health.ucsd.edu</a>
S. Giovanna Carr	UC San Diego, Division of Infectious Diseases & Global Public Health	Clinical Interventionist, Disparities Core	<a href="mailto:s3carr@health.ucsd.edu">s3carr@health.ucsd.edu</a>
Regina Underwood	Program Director, The Neighborhood House Association	CAB Member	<a href="mailto:runderwood@neighborhoodhouse.org">runderwood@neighborhoodhouse.org</a>
Suzanne Afflalo	Medical Director, Alliance Health Clinic	CAB Member	<a href="mailto:suzanneafflalo@sbcglobal.net">suzanneafflalo@sbcglobal.net</a>
Marvin Hanashiro	Community Outreach Coordinator, Antiviral Research Center	CAB Member	<a href="mailto:mhanashiro@health.ucsd.edu">mhanashiro@health.ucsd.edu</a>
Wanda London	Community Member	Guest	<a href="mailto:london.wanda@yahoo.com">london.wanda@yahoo.com</a>
Danielle Campbell	UC San Diego Pre-Doctoral Fellow, Division of Infectious Diseases & Global Public Health	Guest	<a href="mailto:dacampbe@health.ucsd.edu">dacampbe@health.ucsd.edu</a>
Albert Genegaling	Study Coordinator, UC San Diego, Division of Infectious Diseases & Global Public Health	Guest	<a href="mailto:agenegaling@health.ucsd.edu">agenegaling@health.ucsd.edu</a>

Melanie Barker	UC San Diego Pre-Doctoral Fellow, Division of Infectious Diseases & Global Public Health	Guest	<a href="mailto:mbarker@ucsd.edu">mbarker@ucsd.edu</a>
Delilah Bayona	CHIP Team Lead, San Ysidro Health	Guest	<a href="mailto:delilah.bayona@syhealth.org">delilah.bayona@syhealth.org</a>
Betty Uribe	Program Manager, Christie's Place	Guest	<a href="mailto:uribe@christiesplace.org">uribe@christiesplace.org</a>
Jessica Montoya	Clinical Psychologist, UC San Diego	Guest	<a href="mailto:jmontoya@health.ucsd.edu">jmontoya@health.ucsd.edu</a>
Anamaria Ancheta	Undergraduate Student Researcher, Antiviral Research Center	Guest	<a href="mailto:aancheta@ucsd.edu">aancheta@ucsd.edu</a>

### **Commencement**

The CAB meeting began at 09:00 a.m.

### **Welcome from CAB Chair & Co-Chair and Introductions**

Ms. Judi Patterson Disparities Core CAB Co-Chair, and Dr. Jamila K. Stockman, Director Disparities Core CAB, welcomed the group and facilitated introductions of leadership and participants via Zoom video conference. See attendee names, affiliations, and contact information above.

### **Community Symposium Planning for the 2020 National CFAR Meeting**

Dr. Jamila K. Stockman provided an update on the Community Symposium Planning for the 2020 National CFAR Meeting. The 2020 National CFAR Meeting will be held from November 2-6, 2020. The Community Symposium day will be held on November 3, 2020 at 9:00 am PST. She shared her screen and provided an update on the current agenda for the event along with the speakers for the day.

The schedule of presentations for the Community Symposium can be found here: [National CFAR Community Symposium Agenda](#)

There will be Q&A sessions in between each presentation with the speaker(s). Additionally, there will be a panel after HIV Prevention: Focus on PrEP and Retention in Care presentations. In addition, the EHE session will also have a panel discussion. Dr. Jamila K. Stockman asked the CAB members and guests if they knew of an African American/Black male who would be interested in joining the Retention in Care panel.

Ms. Danielle Campbell posed the question, "For the African American male, does he have to be affiliated with UCSD?"

- Dr. Stockman answered, "No, great question Danielle. We are looking for a community member. Preferably someone from the local San Diego community but we are open at this point. But definitely someone from the community and not from an academic institution."
- Ms. Danielle Campbell noted, "that is great. I will e-mail you a recommendation of a great community member that could speak to that."

Dr. Jamila K. Stockman mentioned there will be breakout sessions and networking opportunities at the end of the symposium. An example topic covered in the breakout rooms will be faith and spirituality.

### **COVID-19 Vaccine Trials**

Dr. Susan Little presented on the COVID-19 Vaccine Trials. Dr. Little stated that she is leading a couple of COVID-19 vaccine studies in San Diego and she wanted to focus this meeting regarding challenges with outreach and recruitment.

#### **Outline**

- **COVID-19 Prevention Network (CoVPN)**
  - AstraZeneca
  - Janssen

- **Outreach & Recruitment**

**COVID-19 Prevention Network (CoVPN)**

The COVID-19 Prevention Network is supporting and hosting these studies. This network is part of Operation Warp Speed, which is a partnership of the Department of Health and Human Services and the Department of Defense.

- Goal: To accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnosis.

CoVPN is a functional unit formed by the National Institute of Health (NIH) to respond to the global pandemic.

- The Mission: To conduct Phase III efficacy trials for COVID-19 vaccines and monoclonal antibodies.

**The Vaccine Production Process:** Target for COVID-19 vaccine in 12-18 months, accelerating the process. These timeframes will overlap with one another.

- Research
  - Normal: 2-4 years
  - Accelerated: 6 months
- Preclinical Preparation
  - Normal: 2 years
  - Accelerated: 6 months
- Clinical Trials
  - Normal: Up to 5 years
  - Accelerated: 1.5 years
- Approval
  - Normal: 1 year
  - Accelerated: 6 months
- Manufacturing
  - Normal: 2 years
  - Accelerated: 3-6 months
- Distribution
  - Normal: 3-6 months
  - Accelerated: 1 month

**Primary Objectives:**

- Is the study vaccine safe to give to people?
- Can the study vaccine reduce the severity and frequency of COVID-19 illness?

Dr. Susan Little noted it is not necessary for a vaccine to prevent COVID-19, although it would be great, it is not necessary. If we have a vaccine that reduces the severity of illness and frequency of death of people who get COVID that would still be close to a homerun given how bad this pandemic has been. Dr. Little mentioned the recruitment criteria and stated people will be compensated for their time if they participate. She also noted that there are no plans to do challenged studies, there are no plans to intentionally expose people to COVID-19 to see if the vaccine is protective. The goal is to vaccinate people and follow them in their daily lives.

*Evaluate*

- Participants who have more than 1-day of qualifying symptoms will contact study site
- Tested positive for SARS-CoV-2
- Close follow-up for participants with confirmed positive results

**AstraZeneca Phase III/ CoVPN 3002 – Study Overview**

- Phase III randomized, double blind, placebo-controlled multicenter study assessing the safety, efficacy, and immunogenicity of AZD1222.
- AZD1222 is a replication-deficient simian adenovirus encoding full-length SARS-CoV-2 Spike protein.
- Earlier studies: Side effects were generally mild or moderate and resolved in 1-7 days (fatigue and headache most common symptoms).

**Janssen Phase III – Study Overview**

- A randomized double-blind, placebo controlled study to assess the efficacy and safety of Ad26.COV2.S for the prevention of SARS-CoV-2 mediated COVID-19.
- Ad26.COV2.S is a replication-incompetent adenovirus type 26 vector encoding SARS-CoV-2 spike S protein. Vector used in 26 previous Janssen studies (Ebola, Zika, HIV, etc).
- Phase I/II study: adverse effects generally mild/moderate and resolved within days (injection site, pain, fatigue, headache, and muscle pains most common).
  - In this study, it was found that side effects were more common in younger folks than older folks.
- This is the first international COVID-19 vaccine trial; it will be conducted at 10 sites.

### **Outreach and Recruitment**

Dr. Little presented a graph with Coronavirus cases per 10,000 people. She noted overall there are 38 cases of Coronavirus per 10,000 people. The graph presented was separated by race and ethnicity. This shows that certain racial and ethnic groups are disproportionately impacted compared to their representation in the population. \

- White – 23 per 10,000 people
- All – 28 per 10,000 people
- Black – 62 per 10,000 people
- Latinx – 73 per 10,000 people

### **Build Trust in Vulnerable Communities**

- Lack of trust in healthcare system
  - History of mistreatment
  - Unethical experimentation
  - Criminal neglect
- Low COVID-19 screening rates especially among Black communities
- Community engagement and outreach provided only during a time of national crisis will not build lasting trust
- Indications that the vaccine review process may be undercut by politics has further increased mistrust in the process.

### **NEXUS: Intersectional Stigma on HIV Prevention among Latino MSM**

Dr. Laramie Smith introduced the NEXUS study and stated it is the first of its kind to use social networks as way to examine how Latino MSM experience intersectional stigma, in particular how folks experience racism, homophobia, and bias towards non-adherence to masculinity norms. Dr. Smith noted they are looking to see what the sources and social contexts are of their experiences of stigma and its influences on HIV testing and engagement in PrEP. This will help inform ways social networks and interventions can be built to promote reduction in the harms of intersectional stigma and promote the health and well-being of the community. Dr. Smith stated they are making sure voices are heard in these communities.

Dr. Smith explained folks will be enrolled in a 12-month study. Participants will come back for follow-up assessments throughout the 12-month study period to evaluate potential changes of social network interactions and engagement in HIV care.

### **LinkPositively: Project Update and Resource Locator Review**

Dr. Jamila K. Stockman re-introduced the LinkPositively mobile app project. Dr. Stockman explained the resource locator system – one of 5 components of the LinkPositively mobile app - as a way for participants to have access to important HIV and support service organizations that they may deem helpful. She then showcased the various organizations compiled to date, along with information concerning description, hours of operation, COVID-19 protocol, insurance requirements, eligibility requirements, and preferred scheduling methods. Ms. Janine Lopez stated she and the team will be incorporating more organizations to the list. Dr. Stockman requested that CAB members email Ms. Lopez with any organizations they think will be helpful to have included in the resource locator database.

### **Global CAB Update:**

The Global CAB Committee Meeting took place on September 15, 2020. Ms. Janine Lopez stated the GCAB officially changed their name to *University Community Advisory Board (UCAB)*.

#### **CAB Updates:**

**AVRC CAB:** The AVRC CAB reported they are conducting community outreach for COVID-19. Additionally, they are looking to expand HIV clinical trials but given the current state of COVID-19 it presented difficulties. The AVRC staff is currently working at 25% capacity limiting the amount of trials that can be done.

**Owen CAB:** The Owen CAB has adopted a full mission statement. The CAB is working with Owen Clinic to develop a newsletter that will be broadcasted on their website. A Patient Ambassador Program is currently in the works. This program will pair a mentor with a newly diagnosed HIV patient and help them navigate the HIV care system. The Owen CAB is also working on a guidebook to help patients navigate the MyChart system.

**Transgender/Nonbinary CAB (TCAB):** The TCAB is working on a Best Practices Health Resource Guidebook. They noted the guidebook is under review and will be ready for dissemination in the next couple of weeks. The guide will be posted on the TCAB website for reference. On October 27 at 5:30pm, the TCAB will host a virtual Halloween trivia event. It is the hope that this event will assist in recruitment efforts for TCAB.

### **Adjournment**

Meeting adjourned at 11:00 am